25. equity anD other coMponents of equity (1) Share capital and capital surplus The movement of the number of issued shares and share capital is as follows: Number of authorised  shares  (Thousands of shares) Number of ordinary  issued shares  (Thousands of shares) Share capital  (Millions of yen) Capital surplus  (Millions of yen) As of 1 April 2012 2,000,000 467,964 ¥103,001 ¥176,822 Increase — — — — Decrease — — — — As of 31 March 2013 2,000,000 467,964 103,001 176,822 Increase — — — — Decrease — (11,000) — — As of 31 March 2014 2,000,000 456,964 ¥103,001 ¥176,822 (Note) 1. Decrease in the number of ordinary issued shares during the year ended 31 March 2014 resulted from the cancellation of treasury shares. 2. The Company completed a five-for-one share split with an effective date of 1 April 2014. As a result, the number of authorised shares increased by 7,000,000  thousand shares to 9,000,000 thousand shares, and the number of ordinary issued shares increased by 1,827,858 thousand shares to 2,284,823 thousand shares. (2) Treasury shares The movement of treasury shares is as follows: Number of shares  (Thousands of shares) Amount  (Millions of yen) As of 1 April 2012 6,044 ¥ 23,132 Increase 10,804 49,392 Decrease (60) (239) As of 31 March 2013 16,788 72,285 Increase 5,050 30,075 Decrease (11,102) (47,825) As of 31 March 2014 10,736 ¥ 54,535 (Note) The Company completed a five-for-one share split with an effective date of 1 April 2014. As a result, the number of treasury shares increased by 42,945 thousand  shares to 53,681 thousand shares. (3) Other components of equity Subscription rights to shares Foreign currency translation adjustments The Company adopts share option plans and issues subscription rights to shares under the Companies Act of Japan. Contract  conditions and amounts are described in “27. Share-based payment”. Fair value movements on available-for-sale financial assets This is a foreign currency translation difference that occurred when consolidating financial statements of foreign subsidiaries prepared  in a foreign currency. This is a valuation difference between the fair value and acquisition cost of available-for-sale financial assets, which are measured at  fair values. Astellas Pharma Inc.  _ Annual Report 2014 130